Skip to the content

For media-related inquiries, contact Mona Shater.

News

The latest updates and announcements from the USRDS below:

2021 SAFs Now Available

The 2021 USRDS Standard Analysis Files (SAFs) are now available for request. Contact us at usrds@usrds.org with inquiries.

Posted: 4/7/2022

Now Live: ESRD Quarterly and DESKRIBE Updates

DESKRIBE is now updated with 2021 ADR data and the ESRD Quarterly Update is live with data through the third quarter of 2021.

Posted: 3/16/2022

ESRD Quarterly Update

The end-stage renal disease (ESRD) Quarterly Update with data through the second quarter of 2021 is now available.

Posted: 2/2/2022

USRDS Releases 2021 Interactive Annual Data Report (ADR)

The Chronic Disease Research Group (CDRG), in partnership with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is proud to announce the release of the 2021 USRDS Annual Data Report (ADR).

The report is again presented in a fully interactive format, which was introduced with the 2020 ADR. However, the content has been improved, restructured, and expanded. Building on the COVID-19 Supplement (coronavirus disease 2019) introduced in the 2020 ADR, the ADR’s critical surveillance mission continues by including an updated COVID-19 Supplement that presents many outcomes through the end of 2020 and some through the second quarter of 2021. Quarterly claims data from payment year 2020 is utilized to describe COVID testing and cases, incidence of COVID-related AKI, utilization of therapeutic interventions (e.g., hospitalization, ICU care, mechanical ventilation), and post-discharge outcomes in COVID survivors.)

The COVID pandemic had a significant impact on the ESRD population. The cumulative incidence rate of COVID-19 was twice as high among dialysis patients as among the general population. COVID-19 incidence was also higher for the CKD and transplant populations. As a result, total deaths in the dialysis population increased by nearly 18,000 in 2020 compared with 2019, an increase of almost 20 percent.  Also, reduced rates of initiation of kidney replacement therapy in the early wave of the pandemic resulted in almost 5,000 fewer cases of treated ESRD for the entire year. As a result, the dialysis population had an unprecedented decline of 2 percent due to the COVID-19 pandemic.

Additional updates with the release of this report include:

  • A new chapter on racial and ethnic disparities in healthcare delivery and outcomes in the CKD and ESRD populations
  • A new chapter on home dialysis
  • Elimination of the chapters dedicated to cardiovascular disease, dispersing much of their content into the relevant remaining chapters.

This year’s ADR also includes new or reintroduced sources of data:

  • Optum® de-identified Clinformatics® Data Mart database
  • CMS Medicaid T-MSIS Analytic Files
  • ESRD Quality Reporting System (EQRS) data
  • Medicare Provider Analysis and Review (MedPAR) data

To learn more about these data sources, read the 2021 ADR introductory chapter.

Based on the data in this year’s ADR, the last decade was marked by substantial improvement in several important metrics and clinical outcomes among individuals with CKD and ESRD. Among others, these include:

  • CKD outcomes
    • A 22% reduction in adjusted all-cause mortality among Medicare fee-for-service (FFS) beneficiaries ≥66 years of age with CKD that was more than twice as large as the reduction in mortality observed among beneficiaries without CKD.
    • A 29% reduction in the adjusted rate of all-cause hospitalization among Medicare FFS beneficiaries aged 66 years or older with CKD.
    • A 14% reduction in readmission after hospital discharge among older Medicare FFS beneficiaries with CKD.
  • ESRD outcomes
    • An increase in the percentage of older Medicare beneficiaries with prior CKD initiating dialysis outside of the hospital since 2014, reaching almost 60%.
    • A 7% reduction in adjusted ESRD incidence to 373 per million population in 2019.
    • A 25% reduction in the percentage of patients initiating dialysis with eGFR ≥15 ml/min/1.73m2.
    • An 85% increase in the percentage of incident dialysis patients starting home dialysis, and a 73% increase in the percentage of patients performing home dialysis one year after dialysis initiation.
    • A 61% reduction in the rate of hospitalization for peritonitis and a 36% reduction in the rate of hospitalization for catheter complications among patients performing peritoneal dialysis.
    • A 13% reduction in adjusted rate of all-cause hospitalization among prevalent hemodialysis patients, 14% reduction among prevalent peritoneal dialysis patients, and 11% reduction among kidney transplant recipients. Reductions in the rate of all-cause hospitalization in the first year after dialysis initiation were even larger at 18% for patients treated with hemodialysis and 20% among those performing peritoneal dialysis.
    • A 17.5% reduction in adjusted all-cause mortality among patients on hemodialysis and a 21% reduction among patients performing peritoneal dialysis.
    • Increase in the rate of kidney transplantation among patients with ESRD that began in the second half of the decade – a reversal that followed a period of decline during the first half of the decade.

The USRDS serves the kidney community through research, analysis, and investigator-initiated research. If you have any questions about the 2021 ADR, please contact USRDS.

About the USRDS

The core purpose of the USRDS ADR is to characterize the impact of chronic kidney disease on the US population and to support research and policy initiatives designed to improve the care of individuals with kidney disease. The new report features data accumulated through 2018. Along with producing the ADR on end-stage renal disease and chronic kidney disease in the United States, the USRDS fulfills data requests, provides standard analysis files (SAFs) to researchers, produces the Researcher’s Guide to help researchers use USRDS data, and presents the results of its research at national conferences and in peer-reviewed journals. Learn more by visiting the USRDS website.

About NIDDK

NIDDK research creates knowledge about and treatments for diseases that are among the most chronic, costly, and consequential for patients, their families, and the nation. Learn more by visiting the NIDDK website.

Posted: 12/14/2021

2020 SAFs Now Available

We are happy to announce that the 2020 USRDS Standard Analysis Files (SAFs) are now available for request. 

Posted: 2/25/2021

Now Available: Updated 2017 ESRD and pre-ESRD Part D Data

When first released in March, 2020, the 2017 ESRD Part D data and the 2017 pre-ESRD Part D data in the 2019 USRDS Standard Analysis Files (SAFs) were incomplete. This discrepancy only affected incident ESRD patients whose first service date was June, 2017 or later. These 2017 Part D files are now complete and available for request. If you received the 2017 ESRD Part D or the 2017 pre-ESRD Part D data as part of your USRDS Data Use Agreement (DUA) in 2020, please contact usrds@usrds.org to request updated files.

Posted: 1/7/2021

Legacy RenDER App Departure; New Application System in Place

The USRDS RenDER application has been replaced with a new application system entitled "Data Extraction System for Kidney Related Information & Basic Epidemiology, or DESKRIBE.

DESKRIBE allows users to retrieve information on the entire ESRD population or on precisely specified subgroups of interest. The system is designed to provide a high-level of interactivity and instant feedback, allowing users with varying background and knowledge to navigate the system.

In addition to the two previously existing applications on our website (ESRD Incident Count and ESRD Prevalent Count), two new modules have been added: the ESRD Hospitalization Rate and ESRD Mortality Rate. The ESRD Hospitalization tool can be used to display hospital admission and hospitalized days rate of ESRD patients. The ESRD Mortality Rate tool can be used to display morality rate of ESRD patients. Specific populations of interest and display formats can be tailored to the user's needs.

We welcome your feedback about the apps. Please send questions/comments to usrds@usrds.org.

Posted: 12/1/2020

ESRD Quarterly Update

The end-stage renal disease (ESRD) Quarterly Update with data through the second quarter of 2020 is now available.

Posted: 11/18/2020

USRDS Releases 2020 Interactive Annual Data Report

The Chronic Disease Research Group (CDRG), in partnership with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is proud to announce the next evolution of the United States Renal Data System (USRDS) Annual Data Report (ADR): The 2020 interactive ADR. For the first time in the history of the USRDS, the ADR is fully interactive. Through intuitive, easy-to-use navigation, website users can sort through the volume chapters, customize data representation, and download the tailored information in common data formats.

“According to the recently published Global Burden of Disease in The Lancet, chronic kidney disease (CKD) has risen to the eighth leading cause of disability-adjusted life-years in people aged 50 to 74 years,” said Kirsten L. Johansen, MD, director of the USRDS Coordinating Center in Minneapolis, Minn. “As the United States population ages, the impact of chronic kidney disease and end-stage renal disease (ESRD) on health outcomes and health care spending cannot be overstated.”

Important findings in this year’s Annual Data Report include:

  • A 14.9% prevalence of CKD among US adults
  • A death rate more than twice as high in people with versus without CKD
  • A 40% increase in hospitalizations with acute kidney injury from 2009 to 2018 and a persistently large disparity in acute kidney injury between Black and White patients
  • An increase of only 0.2% in the adjusted rate of end-stage renal disease (ESRD) incidence from 2017 to 2018
  • Strong growth in home dialysis use and preemptive kidney transplant
  • A declining ultrafiltration rate in patients undergoing hemodialysis
  • Lack of progress in catheter use at dialysis initiation, as well as hospitalization and readmission of dialysis patients, but a 1.5% decrease in the death rate of dialysis patients from 2017 to 2018
  • All-time highs in kidney transplants and graft survival among deceased donor transplants
  • Steadily decreasing use of prescription opioids among CKD and ESRD patients from 2009 to 2018
  • 23.2% of Medicare fee-for-service spending in patients with CKD and ESRD and continued growth of Medicare Advantage enrollment of dialysis patients

The 2020 ADR also includes new content:

  • A chapter devoted to the patient experience, including end-of-life care for patients with ESRD
  • An unprecedented look at the impact of COVID-19 on death rates and hospitalizations in patients with ESRD, as well as the incidence of ESRD

“Compared to previous years, dialysis and kidney transplant patient mortality during the spring increased by 37% and 61%, respectively, while hospitalization for non-COVID-related reasons fell by 33%,” says Dr. Johansen. “Remarkably, the number of patients who were newly diagnosed with ESRD declined by almost 20%, illustrating the profound impact of COVID-19 on people with advanced CKD and ESRD.”

"The USRDS has been a critical system for kidney disease surveillance in the United States for more than 30 years," says Dr. Kevin C. Abbott, Director of the Kidney and Urology Epidemiology Program at NIDDK. "In tandem with the Advancing American Kidney Health initiative, this year's ADR represents the beginning of a new era, with interactive presentations of data about CKD and ESRD."

The USRDS serves the kidney community through research, analysis, and investigator-initiated research. If you have any questions about the new interactive ADR, please contact USRDS.

About the USRDS

The core purpose of the USRDS ADR is to characterize the impact of chronic kidney disease on the US population and to support research and policy initiatives designed to improve the care of individuals with kidney disease. The new report features data accumulated through 2018. Along with producing the ADR on end-stage renal disease and chronic kidney disease in the United States, the USRDS fulfills data requests, provides standard analysis files (SAFs) to researchers, produces the Researcher’s Guide to help researchers use USRDS data, and presents the results of its research at national conferences and in peer-reviewed journals. Learn more by visiting the USRDS website.

About NIDDK

NIDDK research creates knowledge about and treatments for diseases that are among the most chronic, costly, and consequential for patients, their families, and the nation. Learn more by visiting the NIDDK website.

Posted: 11/11/2020

Now Live: New and Improved USRDS Website

The United States Renal Data System (USRDS) is proud to announce an expansive redesign of our website.

The redesigned website will provide the kidney community with a streamlined approach to the information that health care professionals, patients, and researchers seek. Updates include sleek, simple website navigation with easy access to the information users visit our website for the most: the Annual Data Report (ADR) and previous ADRs, end-stage renal disease (ESRD) quarterly updates, Standard Analysis File (SAF) requests, simple data requests, and much more.

The USRDS has also expanded its public use tools that are available to researchers. We are developing a new data query system that allows substantial customization by the user. Beta versions of this system for identifying counts of incident and prevalent ESRD patients—with resolution as fine as the county—are now available.

We look forward to continuing to serve the kidney community through research, analysis, and investigator-initiated research. If you have any questions about our website, please contact us.

Posted: 8/6/2020

ESRD Quarterly Update

The end-stage renal disease (ESRD) Quarterly Update with data through the third quarter of 2019 is now available.

Posted: 6/30/2020

2019 SAF Available

We're happy to announce the 2019 USRDS Standard Analysis Files (SAF) is available for request. Contact us with questions or requests.

Claims Error

We identified an issue with the 2012 Institutional ESRD claims. The file didn't include the claims across the first service date for 2012 incident ESRD patients. If your study was approved to use this file, you can contact us to receive an update on the 2012 institutional claims.

Now Available: 2019 ADR

The abbreviated 2019 USRDS Annual Data Report is now available.

RenDER Update

The RenDER system now includes data through 2016.

ESRD Update Available

The ESRD Quarterly Update with data through the third quarter of 2018 is now available.

 

USRDS Coordinating Center (CC)

Tel: 1.888.99USRDS
      (1.888.998.7737)

Email: usrds@usrds.org